<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>1 General Guidelines for Chemotherapy Dosage Based on Hepatic Function | 　　　　</title>
  <meta name="description" content="1 General Guidelines for Chemotherapy Dosage Based on Hepatic Function | 　　　　" />
  <meta name="generator" content="bookdown 0.21 and GitBook 2.6.7" />

  <meta property="og:title" content="1 General Guidelines for Chemotherapy Dosage Based on Hepatic Function | 　　　　" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="1 General Guidelines for Chemotherapy Dosage Based on Hepatic Function | 　　　　" />
  
  
  




  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="part-i-chemotherapy.html"/>
<link rel="next" href="part-ii-oncology.html"/>
<script src="libs/header-attrs-2.7/header-attrs.js"></script>
<script src="libs/jquery-3.5.1/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />









<script src="libs/htmlwidgets-1.5.3/htmlwidgets.js"></script>
<link href="libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="libs/datatables-binding-0.17/datatables.js"></script>
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="libs/nouislider-7.0.10/jquery.nouislider.min.css" rel="stylesheet" />
<script src="libs/nouislider-7.0.10/jquery.nouislider.min.js"></script>
<link href="libs/selectize-0.12.0/selectize.bootstrap3.css" rel="stylesheet" />
<script src="libs/selectize-0.12.0/selectize.min.js"></script>
<link href="libs/dt-plugin-searchhighlight-1.10.20/source.css" rel="stylesheet" />
<script src="libs/dt-plugin-searchhighlight-1.10.20/jquery.highlight.js"></script>
<script src="libs/dt-plugin-searchhighlight-1.10.20/source.min.js"></script>
<link href="libs/crosstalk-1.1.1/css/crosstalk.css" rel="stylesheet" />
<script src="libs/crosstalk-1.1.1/js/crosstalk.min.js"></script>
<link href="libs/tabwid-1.0.0/tabwid.css" rel="stylesheet" />
<script src="libs/es6shim-0.35.6/es6shim.js"></script>
<script src="libs/es7shim-6.0.0/es7shim.js"></script>
<script src="libs/graphre-0.1.3/graphre.js"></script>
<script src="libs/nomnoml-1.3.1/nomnoml.js"></script>
<script src="libs/nomnoml-binding-0.2.3/nomnoml.js"></script>



<link rel="stylesheet" href="css/JhengHei.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="index.html#oncology-geriatrics-and-others"><strong>《Oncology, Geriatrics, and others》</strong></a></li>
<li><a href="part-i-chemotherapy.html#part-i---chemotherapy"><em>Part I - Chemotherapy</em></a></li>
<li class="chapter" data-level="1" data-path="general-guidelines-for-chemotherapy-dosage-based-on-hepatic-function.html"><a href="general-guidelines-for-chemotherapy-dosage-based-on-hepatic-function.html"><i class="fa fa-check"></i><b>1</b> General Guidelines for Chemotherapy Dosage Based on Hepatic Function</a>
<ul>
<li class="chapter" data-level="1.1" data-path="general-guidelines-for-chemotherapy-dosage-based-on-hepatic-function.html"><a href="general-guidelines-for-chemotherapy-dosage-based-on-hepatic-function.html#recommended-dose-reduction-for-hepatic-dysfunction"><i class="fa fa-check"></i><b>1.1</b> Recommended Dose Reduction for Hepatic Dysfunction</a></li>
</ul></li>
<li><a href="part-ii-oncology.html#part-ii---oncology"><em>Part II - Oncology</em></a></li>
<li class="chapter" data-level="2" data-path="prostate-cancer.html"><a href="prostate-cancer.html"><i class="fa fa-check"></i><b>2</b> Prostate Cancer</a>
<ul>
<li class="chapter" data-level="2.1" data-path="prostate-cancer.html"><a href="prostate-cancer.html#staging-system-for-prostate-cancer"><i class="fa fa-check"></i><b>2.1</b> Staging System for Prostate Cancer</a>
<ul>
<li class="chapter" data-level="2.1.1" data-path="prostate-cancer.html"><a href="prostate-cancer.html#definitions-for-t-n-m---prostate-cancer"><i class="fa fa-check"></i><b>2.1.1</b> Definitions for T, N, M - prostate cancer</a></li>
<li class="chapter" data-level="2.1.2" data-path="prostate-cancer.html"><a href="prostate-cancer.html#ajcc-prognostic-groups---prostate-cancer"><i class="fa fa-check"></i><b>2.1.2</b> AJCC Prognostic Groups - prostate cancer</a></li>
</ul></li>
<li class="chapter" data-level="2.2" data-path="prostate-cancer.html"><a href="prostate-cancer.html#diagnosis---prostate-cancer"><i class="fa fa-check"></i><b>2.2</b> Diagnosis - prostate cancer</a>
<ul>
<li class="chapter" data-level="2.2.1" data-path="prostate-cancer.html"><a href="prostate-cancer.html#initial-prostate-cancer-diagnosis"><i class="fa fa-check"></i><b>2.2.1</b> Initial Prostate Cancer Diagnosis</a></li>
<li class="chapter" data-level="2.2.2" data-path="prostate-cancer.html"><a href="prostate-cancer.html#initial-risk-stratification-and-staging-workup---prostate-cancer"><i class="fa fa-check"></i><b>2.2.2</b> Initial Risk Stratification and Staging Workup - Prostate Cancer</a></li>
</ul></li>
<li class="chapter" data-level="2.3" data-path="prostate-cancer.html"><a href="prostate-cancer.html#treatment---prostate-cancer"><i class="fa fa-check"></i><b>2.3</b> Treatment - prostate cancer</a>
<ul>
<li class="chapter" data-level="2.3.1" data-path="prostate-cancer.html"><a href="prostate-cancer.html#systemic-therapy-for-castration-naive-prostate-cancer"><i class="fa fa-check"></i><b>2.3.1</b> Systemic Therapy for Castration-Naive Prostate Cancer</a></li>
<li class="chapter" data-level="2.3.2" data-path="prostate-cancer.html"><a href="prostate-cancer.html#systemic-therapy-for-m0-castration-resistant-prostate-cancer-crpc"><i class="fa fa-check"></i><b>2.3.2</b> Systemic Therapy for M0 Castration-Resistant Prostate Cancer (CRPC)</a></li>
<li class="chapter" data-level="2.3.3" data-path="prostate-cancer.html"><a href="prostate-cancer.html#systemic-therapy-for-m1-castration-resistant-prostate-cancer-crpc"><i class="fa fa-check"></i><b>2.3.3</b> Systemic Therapy for M1 Castration-Resistant Prostate Cancer (CRPC)</a></li>
</ul></li>
<li class="chapter" data-level="2.4" data-path="prostate-cancer.html"><a href="prostate-cancer.html#principles-of-genetics---prostate-cancer"><i class="fa fa-check"></i><b>2.4</b> Principles of Genetics - prostate cancer</a>
<ul>
<li class="chapter" data-level="2.4.1" data-path="prostate-cancer.html"><a href="prostate-cancer.html#germline-testing"><i class="fa fa-check"></i><b>2.4.1</b> Germline Testing</a></li>
<li class="chapter" data-level="2.4.2" data-path="prostate-cancer.html"><a href="prostate-cancer.html#somatic-tumor-testing"><i class="fa fa-check"></i><b>2.4.2</b> Somatic Tumor Testing</a></li>
</ul></li>
<li class="chapter" data-level="2.5" data-path="prostate-cancer.html"><a href="prostate-cancer.html#principles-of-imaging---prostate-cancer"><i class="fa fa-check"></i><b>2.5</b> Principles of Imaging - prostate cancer</a>
<ul>
<li class="chapter" data-level="2.5.1" data-path="prostate-cancer.html"><a href="prostate-cancer.html#goals-of-imaging"><i class="fa fa-check"></i><b>2.5.1</b> Goals of Imaging</a></li>
<li class="chapter" data-level="2.5.2" data-path="prostate-cancer.html"><a href="prostate-cancer.html#efficacy-of-imaging"><i class="fa fa-check"></i><b>2.5.2</b> Efficacy of Imaging</a></li>
<li class="chapter" data-level="2.5.3" data-path="prostate-cancer.html"><a href="prostate-cancer.html#plain-radiography"><i class="fa fa-check"></i><b>2.5.3</b> Plain Radiography</a></li>
<li class="chapter" data-level="2.5.4" data-path="prostate-cancer.html"><a href="prostate-cancer.html#ultrasound"><i class="fa fa-check"></i><b>2.5.4</b> Ultrasound</a></li>
<li class="chapter" data-level="2.5.5" data-path="prostate-cancer.html"><a href="prostate-cancer.html#bone-imaging"><i class="fa fa-check"></i><b>2.5.5</b> Bone Imaging</a></li>
<li class="chapter" data-level="2.5.6" data-path="prostate-cancer.html"><a href="prostate-cancer.html#computed-tomography"><i class="fa fa-check"></i><b>2.5.6</b> Computed Tomography</a></li>
<li class="chapter" data-level="2.5.7" data-path="prostate-cancer.html"><a href="prostate-cancer.html#magnetic-resonance-imaging"><i class="fa fa-check"></i><b>2.5.7</b> Magnetic Resonance Imaging</a></li>
<li class="chapter" data-level="2.5.8" data-path="prostate-cancer.html"><a href="prostate-cancer.html#positron-emission-tomography-pet"><i class="fa fa-check"></i><b>2.5.8</b> Positron Emission Tomography (PET)</a></li>
</ul></li>
<li class="chapter" data-level="2.6" data-path="prostate-cancer.html"><a href="prostate-cancer.html#principles-of-active-surveillance-and-observation"><i class="fa fa-check"></i><b>2.6</b> Principles of Active Surveillance and Observation</a>
<ul>
<li class="chapter" data-level="2.6.1" data-path="prostate-cancer.html"><a href="prostate-cancer.html#advantages-of-active-surveillance"><i class="fa fa-check"></i><b>2.6.1</b> Advantages of active surveillance:</a></li>
<li class="chapter" data-level="2.6.2" data-path="prostate-cancer.html"><a href="prostate-cancer.html#disadvantages-of-active-surveillance"><i class="fa fa-check"></i><b>2.6.2</b> Disadvantages of active surveillance:</a></li>
<li class="chapter" data-level="2.6.3" data-path="prostate-cancer.html"><a href="prostate-cancer.html#advantages-of-observation"><i class="fa fa-check"></i><b>2.6.3</b> Advantages of observation:</a></li>
<li class="chapter" data-level="2.6.4" data-path="prostate-cancer.html"><a href="prostate-cancer.html#disadvantages-of-observation"><i class="fa fa-check"></i><b>2.6.4</b> Disadvantages of observation:</a></li>
</ul></li>
<li class="chapter" data-level="2.7" data-path="prostate-cancer.html"><a href="prostate-cancer.html#principles-of-radiation-therapy"><i class="fa fa-check"></i><b>2.7</b> Principles of Radiation Therapy</a></li>
<li class="chapter" data-level="2.8" data-path="prostate-cancer.html"><a href="prostate-cancer.html#principles-of-surgery"><i class="fa fa-check"></i><b>2.8</b> Principles of Surgery</a></li>
<li class="chapter" data-level="2.9" data-path="prostate-cancer.html"><a href="prostate-cancer.html#principles-of-androgen-deprivation-therapy"><i class="fa fa-check"></i><b>2.9</b> Principles of Androgen Deprivation Therapy</a>
<ul>
<li class="chapter" data-level="2.9.1" data-path="prostate-cancer.html"><a href="prostate-cancer.html#adt-for-clinically-localized-n0m0-disease"><i class="fa fa-check"></i><b>2.9.1</b> ADT for Clinically Localized (N0,M0) Disease</a></li>
<li class="chapter" data-level="2.9.2" data-path="prostate-cancer.html"><a href="prostate-cancer.html#adt-for-regional-n1m0-disease"><i class="fa fa-check"></i><b>2.9.2</b> ADT for Regional (N1,M0) Disease</a></li>
<li class="chapter" data-level="2.9.3" data-path="prostate-cancer.html"><a href="prostate-cancer.html#adt-for-pn1-disease"><i class="fa fa-check"></i><b>2.9.3</b> ADT for pN1 Disease</a></li>
<li class="chapter" data-level="2.9.4" data-path="prostate-cancer.html"><a href="prostate-cancer.html#adt-for-m0-psa-persistencerecurrence-after-rp-or-ebrt-adt-for-m0-castration-naïve-disease"><i class="fa fa-check"></i><b>2.9.4</b> ADT for M0 PSA Persistence/Recurrence After RP or EBRT (ADT for M0 Castration-Naïve Disease)</a></li>
<li class="chapter" data-level="2.9.5" data-path="prostate-cancer.html"><a href="prostate-cancer.html#adt-for-metastatic-castration-naïve-disease"><i class="fa fa-check"></i><b>2.9.5</b> ADT for Metastatic Castration-Naïve Disease</a></li>
<li class="chapter" data-level="2.9.6" data-path="prostate-cancer.html"><a href="prostate-cancer.html#secondary-hormone-therapy-for-m0-or-m1-crpc"><i class="fa fa-check"></i><b>2.9.6</b> Secondary Hormone Therapy for M0 or M1 CRPC</a></li>
</ul></li>
<li class="chapter" data-level="2.10" data-path="prostate-cancer.html"><a href="prostate-cancer.html#section"><i class="fa fa-check"></i><b>2.10</b> 　</a></li>
</ul></li>
<li><a href="part-iii-geriatrics.html#part-iii---geriatrics"><em>Part III - Geriatrics</em></a></li>
<li><a href="part-iv-others.html#part-iv---others"><em>Part IV - Others</em></a></li>
<li class="chapter" data-level="3" data-path="icd-10-cm.html"><a href="icd-10-cm.html"><i class="fa fa-check"></i><b>3</b> ICD 10 CM</a>
<ul>
<li class="chapter" data-level="3.1" data-path="icd-10-cm.html"><a href="icd-10-cm.html#國際疾病分類第十版中英對照檢索"><i class="fa fa-check"></i><b>3.1</b> 國際疾病分類第十版中英對照檢索</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="tfda-atc.html"><a href="tfda-atc.html"><i class="fa fa-check"></i><b>4</b> TFDA ATC</a>
<ul>
<li class="chapter" data-level="4.1" data-path="tfda-atc.html"><a href="tfda-atc.html#藥品藥理治療分類-atc-code"><i class="fa fa-check"></i><b>4.1</b> 藥品藥理治療分類 ATC Code</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="tfda-ahfsdi.html"><a href="tfda-ahfsdi.html"><i class="fa fa-check"></i><b>5</b> TFDA AHFS/DI</a>
<ul>
<li class="chapter" data-level="5.1" data-path="tfda-ahfsdi.html"><a href="tfda-ahfsdi.html#藥品藥理治療分類-ahfsdi-code"><i class="fa fa-check"></i><b>5.1</b> 藥品藥理治療分類 AHFS/DI Code</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="frequently-used-links.html"><a href="frequently-used-links.html"><i class="fa fa-check"></i><b>6</b> Frequently Used Links</a>
<ul>
<li class="chapter" data-level="6.1" data-path="frequently-used-links.html"><a href="frequently-used-links.html#醫藥參考"><i class="fa fa-check"></i><b>6.1</b> 醫藥參考</a></li>
<li class="chapter" data-level="6.2" data-path="frequently-used-links.html"><a href="frequently-used-links.html#藥物辨識"><i class="fa fa-check"></i><b>6.2</b> 藥物辨識</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="memo.html"><a href="memo.html"><i class="fa fa-check"></i><b>7</b> Memo</a>
<ul>
<li class="chapter" data-level="7.1" data-path="memo.html"><a href="memo.html#daily"><i class="fa fa-check"></i><b>7.1</b> Daily</a></li>
<li class="chapter" data-level="7.2" data-path="memo.html"><a href="memo.html#code"><i class="fa fa-check"></i><b>7.2</b> Code</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">　　　　</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="general-guidelines-for-chemotherapy-dosage-based-on-hepatic-function" class="section level1" number="1">
<h1><span class="header-section-number">1</span> General Guidelines for Chemotherapy Dosage Based on Hepatic Function</h1>
<div id="recommended-dose-reduction-for-hepatic-dysfunction" class="section level2" number="1.1">
<h2><span class="header-section-number">1.1</span> Recommended Dose Reduction for Hepatic Dysfunction</h2>
<div id="htmlwidget-68355f296d21afcfaaef" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-68355f296d21afcfaaef">{"x":{"filter":"top","filterHTML":"<tr>\n  <td><\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n    <\/div>\n  <\/td>\n<\/tr>","data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147"],["Abemaciclib","Acalabrutinib","Afatinib","Alectinib","Alemtuzumab","Altretamine","Amifostine","Aminoglutethimide","Amsacrine","Anastrozole","Apalutamide","Arsenic trioxide","Asparaginase","Atezolizumab","Avelumab","Axicabtagene ciloleucel","Azacitidine","Belinostat","Bendamustine","Bevacizumab","Bicalutamide","Bleomycin","Blinatumomab","Bosutinib","Brigatinib","Buserelin","Busulfan","Cabozantinib","Capecitabine","Carboplatin","Carfilzomib","Carmustine","Ceritinib","Cetuximab","Chlorambucil","Cisplatin","Cladribine","Copanlisib","Cyclophosphamide","Cytarabine","Dabrafenib","Dacarbazine","Dactinomycin","Daratumumab","Daunorubicin","Daunorubicin and cytarabine liposome","Decitabine","Docetaxel","Doxorubicin","Doxorubicin liposome","Durvalumab","Elotuzumab","Enasidenib","Eribulin","Erlotinib","Estramustine","Etoposide","Etoposide","phosphate","Everolimus","Floxuridine","Fludarabine","5-Fluorouracil","Flutamide","Gefitinib","Gemcitabine","Gemtuzumab","Goserelin","Hydroxyurea","Ibrutinib","Idarubicin","Ifosfamide","Imatinib","Inotuzumab","Interferon-alpha","Interleukin-2","Irinotecan","Irinotecan liposome","Isotretinoin","Ixabepilone","Ixazomib","Lapatinib","Lenalidomide","Lenvatinib","Leuprolide","Lomustine","Lutetium Lu 177 dotatate","Mechlorethamine","Megestrol acetate","Melphalan","6-Mercaptopurine","Methotrexate","Mitomycin-C","Mitotane","Mitoxantrone","Necitumumab","Nelarabine","Neratinib","Nilutamide","Niraparib","Nivolumab","Obinutuzumab","Ofatumumab","Olaparib","Osimertinib","Oxaliplatin","Paclitaxel","Palbociclib","Panitumumab","Pazopanib","Pegasparaginase","Pembrolizumab","Pemetrexed","Pertuzumab","Pomalidomide","Ponatinib","Pralatrexate","Procarbazine","Ramucirumab","Regorafenib","Ribociclib","Rituximab","Rituximab and hyaluronidase human","Rucaparib","Sonidegib","Sorafenib","Streptozocin","Sunitinib","Tamoxifen","Temozolomide","Thalidomide","Thioguanine","Thiotepa","Tisagenlecleucel","Topotecan","Trabectedin","Trametinib","Trastuzumab","Tretinoin","Trifluridine/tipiracil","Vemurafenib","Venetoclax","Vinblastine","Vincristine","Vinorelbine","Vorinostat","Ziv-aflibercept"],["No dose reduction for Child-Pugh Class A and B hepatic dysfunction. Has not been studied in setting of severe hepatic dysfunction.","No dose reduction for Child-Pugh Class A and B hepatic dysfunction. Has not been studied in setting of severe hepatic dysfunction.","No dose reduction for Child-Pugh Class A and B hepatic dysfunction. Has not been studied in patients with Child-Pugh Class C hepatic dysfunction, and dose reduction may be necessary in this setting.","No dose reduction is necessary for mild hepatic dysfunction. Has not been studied in setting of moderate to severe hepatic dysfunction.","N/A","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction is necessary.","Reduce dose by 25% if bilirubin >2.0 mg/dL.","No formal recommendation for dose reduction. Dose reduction may be necessary in patients with hepatic dysfunction.","No dose reduction for Child-Pugh Class A and B hepatic dysfunction. Has not been studied in setting of severe hepatic dysfunction.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction. hepatic","No dose reduction for mild or moderate hepatic dysfunction. Has not been studied in setting of severe hepatic dysfunction. hepatic","N/A","No dose reduction is necessary.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction. hepatic","Use with caution in patients with mild hepatic dysfunction. Omit in the presence of moderate (SGOT or SGPT 2.5– 10 × ULN and total bilirubin >1.5 × ULN) or severe (total bilirubin >3 × ULN) hepatic dysfunction.","N/A","No formal recommendation for dose reduction. Dose reduction may be necessary when bilirubin >3.0 mg/dL.","No dose reduction is necessary.","N/A","Reduce dose to 200 mg PO daily in patients with mild, moderate, or severe hepatic dysfunction.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction for mild hepatic dysfunction. Omit in setting of moderate or severe hepatic dysfunction.","No formal recommendation for dose reduction. Patients need to be closely monitored in setting of moderate or severe hepatic dysfunction.","No dose reduction is necessary.","N/A","No dose reduction is necessary.","No dose reduction for mild hepatic dysfunction. Patients need to be closely monitored in setting of moderate or severe hepatic dysfunction, and dose reduction may be necessary.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction for mild hepatic dysfunction. Has not been studied in patients with moderate or severe hepatic dysfunction (total bilirubin ≥1.5 × ULN, any SGOT).","Reduce by 25% if bilirubin 3.0-5.0 mg/dL or SGOT >180 mg/dL.","No formal recommendation for dose reduction.","No dose reduction is necessary for mild hepatic dysfunction. Dose reduction may be necessary with moderate or severe hepatic dysfunction.","No dose reduction is necessary.","Reduce dose by 50% if bilirubin >3.0 mg/dL.","No dose reduction for mild hepatic dysfunction. Has not been studied in patients with moderate or severe hepatic dysfunction.","Reduce dose by 25% if bilirubin 1.5-3.0 mg/dL. Reduce dose by 50% if bilirubin >3.0 mg/dL. Omit if bilirubin >5.0 mg/dL.","No dose reduction for patients with serum bilirubin <3 mg/dL. Has not been studied in patients with serum bilirubin >3 mg/dL, and caution should be used in this setting.","N/A","Omit if bilirubin >1.5 mg/dL, SGOT >60 mg/dL, or alkaline phosphatase >2.5 × ULN.","Reduce dose by 50% if bilirubin 1.5-3.0 mg/dL. Reduce dose by 75% if bilirubin 3.1-5.0 mg/dL. Omit if bilirubin >5.0 mg/dL.","Reduce dose by 50% if bilirubin 1.5-3.0 mg/dL. Reduce dose by 75% if bilirubin 3.1-5.0 mg/dL. Omit if bilirubin >5.0 mg/dL.","No dose reduction for mild hepatic dysfunction. Has not been studied in the setting of moderate or severe hepatic dysfunction.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","Dose should be reduced to 1.1 mg/m2 in patients with mild hepatic dysfunction and to 0.7 mg/m2 in patients with moderate hepatic dysfunction. Has not been studied in setting of severe hepatic dysfunction.","No formal recommendations for dose reduction. Dose reduction or interruption should be considered in patients with severe hepatic dysfunction and/or in those with a bilirubin >3 × ULN.","No dose reduction is necessary.","Reduce dose by 50% if bilirubin 1.5-3.0 mg/dL or SGOT 60-180 mg/dL.","Reduce dose by 50% if bilirubin 1.5-3.0 mg/dL or SGOT","60-180 mg/dL. Omit if bilirubin >3 mg/dL or SGOT >180 mg/dL.","Reduce dose to 5 mg/day in setting of moderate hepatic dysfunction (Child-Pugh Class B).","No dose reduction is necessary.","No dose reduction is necessary.","No formal recommendations for dose reduction. Omit if bilirubin >5.0 mg/dL.","No formal recommendation for dose reduction. Dose reduction may be necessary if bilirubin >3.0 mg/dL.","No formal recommendations for dose reduction. Dose reduction or interruption should be considered in patients with severe hepatic dysfunction.","No dose reduction is necessary.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction is necessary.","No dose reduction is necessary.","No formal recommendations for dose reduction in pres- ence of hepatic dysfunction, and dose reduction may be","Reduce dose by 25% if bilirubin 1.5-3.0 mg/dL or SGOT 60-180 mg/dL.","No dose reduction is necessary.","Reduce dose from 400 mg to 300 mg or from 600 mg to 400 mg if bilirubin >1.5 or SGOT >2.5 × ULN.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction is necessary.","Omit if signs of hepatic failure (ascites, encephalopathy, jaundice) are observed. Do NOT restart sooner than 7 weeks after recovery from severe hepatic dysfunction.","No formal recommendation for dose reduction in presence of hepatic dysfunction. Dose reduction may be necessary.","N/A","No formal recommendation for dose reduction in presence of mild or moderate hepatic dysfunction. Dose reduction may be necessary.","Omit when used in combination with capecitabine if SGOT or SGPT >2.5 × ULN or bilirubin >1 × ULN. When used as monotherapy, dose reduce to 32 mg/m2 if SGOT or SGPT ≤10 × ULN and bilirubin ≤1.5 × ULN and dose reduce to 20–30 mg/m2 if SGOT or SGPT ≤10 × ULN and bilirubin >1.5 × ULN to ≤3 × ULN.","No dose reduction for mild hepatic dysfunction. Dose should be reduced in patients with moderate or severe hepatic dysfunction.","No formal recommendation for dose reduction in presence of mild or moderate hepatic dysfunction. Reduce dose to 750 mg/day in setting of severe hepatic dysfunction (Child-Pugh Class C).","No formal recommendations for dose reduction.","No dose reduction for mild or moderate hepatic dysfunction.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction for mild or moderate hepatic dysfunction. Has not been studied in patients with severe hepatic dysfunction (total bilirubin >3 × ULN and any SGOT, and caution should be used in this setting.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction is necessary.","No dose reduction is necessary.","Reduce dose by 25% if bilirubin 3.1-5.0 mg/dL or SGOT >180 mg/dL.","No dose reduction is necessary.","No formal recommendation for dose reduction in presence of hepatic dysfunction. Dose reduction may be necessary.","No formal recommendation for dose reduction in presence of hepatic dysfunction. Dose reduction may be necessary","No dose reduction for mild or moderate hepatic dysfunc- tion. Has not been studied in setting of severe hepatic dysfunction.","N/A","No dose reduction for mild or moderate hepatic dysfunc- tion. Has not been studied in setting of severe hepatic dysfunction.","No formal recommendation for dose reduction. Dose reduction may be necessary if bilirubin >3.0 mg/dL.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","Has not been studied in setting of hepatic dysfunction.","N/A","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction for mild or moderate hepatic dysfunc- tion. Has not been studied in setting of severe hepatic dysfunction.","No dose reduction is necessary.","No formal recommendation for dose reduction if bilirubin 1.5-3.0 mg/dL or SGOT 60-180 mg/dL.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction is necessary.","Reduce dose to 200 mg/day in setting of moderate hepatic dysfunction.","No dose reduction is necessary.","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction is necessary.","N/A","Omit if bilirubin >2.0 mg/dL and SGOT/SGPT >3 × ULN.","Reduce dose to 30 mg PO daily if SGOT/SGPT >3 × ULN. Omit if SGOT/SGPT  ≤3 × ULN and bilirubin >2 × ULN","N/A","No formal recommendation for dose reduction in presence of hepatic dysfunction. Dose reduction may be necessary.","N/A","No dose reduction for mild or moderate hepatic dysfunction.","No dose reduction for mild hepatic dysfunction. A reduced starting dose of 400 mg is recommended in patients with moderate or severe hepatic dysfunction.","No dose reduction is necessary.","N/A","No dose reduction for mild hepatic dysfunction. Has not been studied in setting of moderate or severe hepatic dysfunction.","No dose reduction is necessary.","No formal recommendation for dose reduction in presence of hepatic dysfunction.","No dose reduction is necessary.","No dose reduction for Child-Pugh Class A or B hepatic dysfunction.","No dose reduction is necessary.","No dose reduction is necessary.","N/A","Omit if bilirubin >5.0 mg/dL.","No formal recommendation for dose reduction in presence of hepatic dysfunction.","N/A","No dose reduction is necessary.","No dose reduction for mild hepatic dysfunction. Dose reduction is necessary in presence of moderate","No dose reduction for mild hepatic dysfunction. Dose reduction may be necessary in patients with moder-","No dose reduction is necessary.","Reduce dose to a maximum of 25 mg/m2 if bilirubin 3.1-5.0 mg/dL or SGOT >180 mg/dL.","No dose reduction for mild hepatic dysfunction. Has not been studied in patients with moderate or severe hepatic dysfunction.","No dose reduction for mild or moderate hepatic dysfunc- tion. Dose reduction may be required with severe hepatic dysfunction.","No dose reduction for mild or moderate hepatic dysfunc- tion. Has not been studied in patients with severe hepatic dysfunction.","No dose reduction if bilirubin <1.5 mg/dL and SGOT <60 mg/dL.","No dose reduction if bilirubin <1.5 mg/dL and SGOT <60 mg/dL.","No dose reduction if bilirubin <2.0 mg/dL. Reduce dose by 50% if bilirubin 2.0-3.0 mg/dL.","N/A","No dose reduction is necessary in patients with mild or moderate hepatic dysfunction. Has not been studied in setting of severe hepatic dysfunction, and dose reduction may be necessary."]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Recommended Dose Reduction for Hepatic Dysfunction<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"pageLength":10,"lengthMenu":[10,100,1000],"searchHighlight":true,"search":{"regex":false,"caseInsensitive":true},"autoWidth":true,"order":[],"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>

</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="part-i-chemotherapy.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="part-ii-oncology.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
